GPRC5D Targeted PET/CT Imaging in Plasma Cell Disorders
Trial statusNot yet recruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-80
SponsorPeking University First Hospital
About this trial
This is a prospective, single-center, single-arm Phase I study evaluating GPRC5D-targeted PET/CT imaging in patients with plasma cell disorders, including multiple myeloma.
Participants will undergo GPRC5D-targeted PET/CT, 18F-FDG PET/CT, and 68Ga-BCMA PET/CT within 5 days whenever feasible for head-to-head comparison of lesion detection and disease assessment.
The study aims to evaluate the safety, feasibility, biodistribution, and diagnostic performance of GPRC5D-targeted PET/CT and to compare its imaging characteristics with currently available molecular imaging modalities in plasma cell disorders.
Eligibility criteria
Qualifiers
Adults with confirmed or suspected plasma cell disorders, including multiple myeloma.
Healthy volunteers eligible for PET/CT imaging may also be enrolled.
Availability of recent clinical laboratory results within 1 week prior to imaging, when applicable.
Ability to undergo PET/CT imaging procedures.
Disqualifiers
History of other active malignant tumors, unless considered clinically insignificant by the investigator.
Pregnant or breastfeeding women.
Inability to understand study procedures or comply with imaging examinations.
Any medical or psychiatric condition that, in the investigator's judgment, may interfere with study participation or image interpretation.
Trial design
Treatments tested in this trial
- GPRC5D-Targeted PET/CT Imaging
Treatment groups
50 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov